Type:Injection
Generic Name:Salmon Calcitonin
Manufacturer:Novartis Pharma AG, Switzerland
Price:৳593.24
Hypercalcaemia, Paget's disease of bone, Postmenopausal osteoporosis.
Parenteral Hypercalcemia Initial dose: 4 IU/kg SC/IM q12hr May increase to 8 IU/kg SC/IM q12hr; may increase up to a maximum 8 IU/kg q6hr if unresponsive Paget Disease Initial dose: 100 IU SC/IM qDay Maintenance: 50 IU/day or 50-100 IU every 1-3 days Osteoporosis, Postmenopausal Indicated for the treatment of postmenopausal osteoporosis in women greater than 5 yr postmenopause 100 IU SC/IM every other day with calcium and vitamin D Nasal Spray: 1 spray (200 IU) qDay, alternate nostrils daily
Safety and efficacy not established
Hypersensitivity.
It inhibits osteoclastic bone resorption and reduces bone turnover. It decreases tubular reabsorption and promotes renal excretion of Ca, Cl, Na, Mg, K and phosphate.
Children <18 yr, renal impairment. Pregnancy, lactation. Serious hypersensitivity reactions, including fatal anaphylaxis, reported; consider skin testing prior to treatment. Hypocalcemia associated with tetany has been reported; ensure adequate intake of calcium and vitamin D Lactation: excretion in milk unknown/not recommended
>10% Rhinitis (12%) 1-10% Arthralgia (4%),Back pain (5%),Expistaxis (4%),Injection site reactions (10%),Nausea (10%),Headache (3%),Flushing of face or hands (2-5%) <1% Abdominal pain,Possible allergic reactions,Appetite decreased,Edema of feet,Eye pain,Feverish sensation,Nausea,Nocturia,Possible local irritative effects in the respiratory tract,Salty taste Frequency Not Defined Tremors Potentially Fatal: Anaphylactic shock.
Concurrent use w/ cardiac glycosides (e.g. digitalis) or Ca-channel blockers requires dosage adjustments of these drugs. May decrease serum concentration of lithium.